JPMorgan removed Ideaya Biosciences from the firm’s Analyst Focus List while keeping an Overweight rating on the shares. The analyst still sees a favorable outlook but believes the Street is largely expecting positive data from the company sponsored darovasertib trial in neoadjuvant uveal melanoma in the second half of 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Ideaya Biosciences price target lowered to $66 from $69 at JPMorgan
- Ideaya Biosciences price target lowered to $53 from $60 at Oppenheimer
- Ideaya Biosciences reports Q2 EPS (68c), consensus (53c)
- IDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
- Ideaya Biosciences enters option, license agreement for B7H3/PTK7 BsADC program